Subscribe Now
 Already a subscriber? Log-in!
The monthly Laboratory Industry Report delivers expert perspective and trusted guidance on critical regulatory updates, operational and financial trends, plus trusted forecasts on the future of the diagnostic laboratory industry.
As a member of the Laboratory Industry Report community, you’ll take advantage of over 30 years of experience including:
- Expert strategies and advice on healthcare integration, capitation, lab technology and more
- Analysis of regulatory impact and relevant details on proposed legislation
- Comparative data on diagnostic lab test pricing and volumes
- Benchmarks to gauge your lab operations versus the diagnostic lab market at large
- Details on publicly-held labs, including executive earnings and performance
- Updates on industry mergers, acquisitions and alliances and large labs’ business activities
Laboratory Industry Report gives you direct access to industry experts to keep you current and informed on the latest issues affecting diagnostic laboratories across practice settings – hospital, commercial, group practice sites and network systems.
Clients find their membership to “LIR” to be much more than a news source; it’s where they to turn for business intelligence and exclusive insight on what's happening to key companies, how Wall Street views the industry, or the latest on mergers, buyouts, consolidations and alliances.
For over 30 years Laboratory Industry Report is a trusted resource for everyone with a vital stake in today's competitive diagnostic lab marketplace – from owners, directors, pathologists, CEOs, COOs, and CFOs to general managers, administrators, lab managers, and sales/marketing professionals.
As always Laboratory Industry Report, guarantees the accuracy, objectivity, and authority of its actionable
intelligence.
Gain a competitive edge for your diagnostic lab!
|
|
|
 |
 | LIR July 2009 (full PDF issue) |
| TOP OF THE NEWS
G-2-Chi Solutions’ Outreach Survey assesses profitability
LabCorp plans to acquire Monogram for $155M
REGULATORY DEVELOPMENTS
Senate bill proposes ‘date of service’ change
FIRST QUARTER BENCHMARKING
Genoptix, Myriad Genetics continue to lead
NEW PARTNERSHIPS
Psychemedics partners with UK’s Bupa
INSIDE THE LAB INDUSTRY
G-2-Chi Solutions survey finds outreach annual revenue growth over 3%
The C-Suite perspective on outreach investment
INDUSTRY NEWSMAKERS
Agendia opens California CLIA lab
GE announces no-interest EMR purchasing options
CBLPath opens NYC location
Adeona Pharma buys Hartlab
FINANCIAL
Lab index up 32% over past 13 weeks
INDUSTRY BUZZ
CDC launches Laboratory Medicine Best Practices
Full Article |
| LabCorp Plans to Acquire Monogram Biosciences for Approximately $155 Million |
| Looking to expand its molecular diagnostic portfolio, LabCorp (Burlington, N.C.) has agreed to acquire Monogram Biosciences (South San Francisco, Calif.), a manufacturer of pharmacogenomic tests or companion diagnostics. According to the merger agreement, LabCorp will acquire all outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million, which includes net indebtedness. The deal is expected to close by the end of the third quarter.
Full Article |
| G-2 Reports-Chi Solutions’ Outreach Survey Indicates Labs Leading in Profitability Measures, Falling Short on Bad Debt and DSO |
| Outreach laboratories are enjoying 20 percent to 27 percent profitability, based on contribution margin or pretax income, compared to Quest Diagnostics’ 13.7 percent and LabCorp’s 17.8 percent for 2008, according to results from the 8th Annual National Outreach Survey, conducted by Washington G-2 Reports and Chi Solutions. Revenue per requisition is also up to $65.95 for 2008, compared to $43 for Quest (Madison, N.J.) and $38.38 for LabCorp (Burlington, N.C.). However, the survey of over 150 respondents found that outreach programs still have significantly higher days sales outstanding (DSO) and bad debt rates compared to the national competitors—two metrics under close scrutiny during this economic environment.
Full Article |
| Senate Bill Proposes ‘Date of Service’ Policy Change That Will Benefit Labs |
| The recently introduced Patient Access to Critical Lab Tests Act (S.1220) will revise a current Medicare billing regulation involving hospital patients receiving testing from independent laboratories within 14 days of discharge. The bill, introduced by Sens. Arlen Specter (D-Pa.) and Ron Wyden (D-Ore.), will help to alleviate access problems resulting from advanced diagnostic testing—often genetic and esoteric testing—that is ordered after a patient’s stay in the hospital, say industry experts. A companion bill was introduced in the House in March.
Full Article |
| Genoptix, Myriad Genetics Lead in G-2 Reports’ First Quarter Benchmarking Analysis |
| For the beginning of 2009, San Diego-based Genoptix and Salt Lake City-based Myriad Genetics appear to be leading the publicly traded labs in two key benchmarking measures tracked by Washington G-2 Reports—revenue per full-time employee (FTE) and pretax income per FTE (see Table 1).
Full Article |
| Psychemedics Teams With UK’s Bupa to Market Hair Analysis Assay |
| Acton, Mass.-based drug testing provider Psychemedics will market its hair analysis diagnostic services in the United Kingdom through a recently announced agreement with Bupa Wellness, the health assessment division of one of the largest health care providers in the country. Bupa Wellness currently offers urine and oral fluid testing, and will now be offering Psychemedics hair analysis testing services in its workplace screening programs—whether pre-employment, random, or related to specific incidents.
Full Article |
| Inside the Lab Industry: Washington G-2 Reports-Chi Solutions’ Latest Survey Finds Outreach Lab Profitability Over 20% and Annual Revenue Growth Over 3% |
|
A majority of hospitals are seeing a moderate or significant decline in their financial health versus last year, with over 40 percent of hospitals expecting to report losses in the first quarter of 2009, according to over 1,000 responses to a survey of American Hospital Association members taken earlier this year. But outreach hospital laboratory operations appear to be weathering the recession. Analysis of data from over 150 respondents to the 8th Annual National Outreach…
Full Article |
| The C-Suite Perspective: Building a Business Case for Outreach |
| For outreach programs to grow and thrive, industry experts at the conference emphasized that labs need the support of senior hospital executives. In a keynote presentation titled “Know Your Numbers,” Michael Metzler, the former COO of St. Elizabeth’s Medical Center (Boston) and CEO of St. Anne’s Hospital (Fall River, Mass.), provided a valuable window into the mind of a CEO considering a move into outreach testing. Metzler prefaced his discussion of how to make the business case for outreach with a warning. “The lab must have a reputation for excellence before outreach can be sold to the CEO,” he said. “Weaknesses must be fixed before making the case for outreach.”
Full Article |
| Agendia Boosts MammaPrint Sales Effort Through CLIA Lab Launch, Sales Force Expansion |
| With the recent opening of a 3,500-square-foot CLIA laboratory in California, the Amsterdam-based molecular diagnostic cancer testing manufacturer Agendia appears to be increasing its efforts to drive adoption of its MammaPrint test in the United States. The Amsterdam-based company also plans on doubling its sales force this year in the United States to increase this year’s MammaPrint volume, said Vice President of Sales and Marketing Daniel Forche, who started with the company last year.
Full Article |
| GE’s $100 Million Stimulus Simplicity Program to Offer No-Interest Loans for EMR Products |
| GE has committed $100 million to a new program, Stimulus Simplicity, which will offer interest-free loans for physicians and hospitals that purchase the company’s Centricity EMR products and enterprise solutions. GE Capital will provide the financing and GE Healthcare will provide the electronic medical record (EMR) product and certification warranty. EMR certification is a precursor to access the federal stimulus reimbursement funding that is part of the HITECH Act of the American Recovery and Reinvestment Act (ARRA).
Full Article |
| Adeona Pharma Buys Chicago’s Hartlab to Expand Degenerative Disease Diagnostic Offerings |
| Ann Arbor, Mich.-based Adeona Pharmaceuticals has announced plans to buy Hartlab, a Bolingbrook, Ill.-based CLIA-certified lab that currently provides same-day service near its headquarters in Chicago and next-day testing services to physicians in other states, with the exception of California, Florida, and New York.
Full Article |
| CBLPath Opens Manhattan Facility |
| Specialized anatomic pathology testing provider CBLPath has opened a second facility located in Manhattan, as part of a focus to expand its physician client base in the lucrative New York City market. CBLPath’s main laboratory is a 66,000-square-foot facility in Rye Brook, N.Y.
Full Article |
| Lab Stocks Continue Impressive Show of Strength; Up 11% Over Five Weeks, 32% Over Past 13 Weeks |
| As seen in late April through mid-May, lab stocks continue to be strong so far in June. Over the past five weeks, the 14 publicly traded labs tracked by the G-2 Reports Laboratory Stock Index are up an impressive 32 percent over the past 13 weeks and 11 percent over the past five weeks for the week ended June 19, 2009. So far in 2009, the index is up 21 percent. The Nasdaq also continues to post gains, although the S&P 500 continues to decline—although not as much as in recent months. For 2009, the Nasdaq is up over 11 percent, while the S&P 500 is down 1.13 percent so far this year.
Full Article |
| Industry Buzz: CDC Seeks Help in Establishing Laboratory Best Practices |
| As Congress takes aim at revamping health care, the Centers for Disease Control and Prevention (CDC) are launching an effort to establish best practices in laboratory medicine. Called the Laboratory Medicine Best Practices (LMBP) project, the goal is to provide evidence-based methods that laboratory professionals can use to evaluate practice effectiveness for improving the quality of health care, to build a more robust knowledge base for the field based on the results of systematic evidence reviews, and to improve health care quality outcomes by identifying pre- and post-analytic practices that effectively improve the use laboratory testing.
Full Article |
|
|
Please choose an archived issue to view newsletter table of contents above
|
|
